2026 AHA CME Symposium - Inflammation as a Therapeutic Target in ASCVD

HAZLET, N.J. - EntSun -- Clinicians have had limited exposure to education specifically addressing inflammatory risk identification and management. Therefore, in this symposium, experts will provide attendees with a comprehensive review of the therapeutic landscape and equip the audience with a practical framework for identifying and managing residual CV inflammatory risk in their patients.

Click here for more information

CHAIR
Paul M. Ridker, MD, MPH
Eugene Braunwald Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular Disease Prevention
Brigham and Women's Hospital
Boston, Massachusetts

FACULTY
Jean-Claude Tardif, CM, MD
Professor of Medicine
Université de Montréal
Director
Montreal Heart Institute Research Center

More on EntSun News

• Boston Industrial Solutions Launches New and Improved Siliart Website for Silicone Decorators
• Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Phoenix
• Sky Quarry's Big Turning Point: CEO Marcus Laun Outlines the Next Phase for N A S D A Q: SKYQ
• Award-Winning Podcast "What Fresh Hell" Marks 10th Anniversary and 1000 Original Episodes
• VIMooZ Cinema Gives Independent Filmmakers a New Way to Distribute and Monetize Their Films

Montreal, Quebec, Canada

Katherine Tuttle, MD
Executive Director for Research
Providence Inland Northwest Health
Spokane, Washington
Professor of Medicine
University of Washington School of Medicine
Seattle, Washington

Educational Objectives

• Describe the role of the IL-1βgIL-6gCRP inflammatory pathway in atherosclerotic plaque progression and rupture, and explain the clinical evidence supporting hsCRP as an independent predictor of recurrent MACE in statin-treated patients with ASCVD
• Identify patients across cardiology subspecialties with established ASCVD and residual inflammatory risk, and apply a structured hsCRP screening and interpretation framework to clinical decision-making
• Discuss the mechanism, clinical outcomes evidence, safety profile, and appropriate patient selection for low-dose colchicine as the current standard of evidence-based anti-inflammatory secondary prevention
• Recognize that inflammation is not only a central mediator in the pathological progression of CKM syndrome but also a pivotal molecular hub that drives coordinated damage across multiple organ systems

Target Audience

More on EntSun News

• Hunter Is Releasing New Music For The Holidays!
• Tixpool.com - Naija Premier Event Reseller
• Work 365 Expands Distributor Integrations with Companial for Microsoft Partners
• Blood Pact Films Brings Supernatural Horror Wiccan's Lair To Audiences
• Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity

This program is intended for cardiovascular clinicians.

Educational Grant
Voxmedia International gratefully acknowledges the educational grant from Novo Nordisk Inc.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia, LLC designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.